Prolonged-release oxycodone-naloxone for pain management in advanced EGFR wild-type lung cancer patients

被引：1
|
作者：
Stella, Giulia M. [1 ]
Piloni, Davide [2 ]
Ciuffreda, Antonio [1 ]
Spiaggi, Ernestina [1 ]
Marino, Elisa [1 ]
Ilardi, Marcella [3 ]
Cavalloro, Fabrizio [3 ]
机构：
[1] San Matteo Polyclin & Inst Res & Care, Sect Pneumol, Dept Cardiothorac Surg, I-27100 Pavia, Italy
[2] Univ Pavia, Dept Internal Med, Unit Pneumol, Pavia, Italy
[3] San Matteo Polyclin & Inst Res & Care, Emergency Dept, Pain Unit, Pavia, Italy
来源：
MINERVA MEDICA | 2018年 / 109卷 / 04期
关键词：
D O I：
10.23736/S0026-4806.18.05287-4
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：337 / 340
页数：5
相关论文
共 50 条
  • [41] Low-dose oral prolonged-release oxycodone/naloxone for chronic pain in elderly patients with cognitive impairment: an efficacy-tolerability pilot study
    Petro, Emiliano
    Ruffini, Elena
    Cappuccio, Melania
    Guerini, Valeria
    Belotti, Gloria
    Fascendini, Sara
    Licini, Cristina
    Marcassa, Claudio
    NEUROPSYCHIATRIC DISEASE AND TREATMENT, 2016, 12 : 559 - 569
  • [42] EGFR endocytosis is a novel therapeutic target in lung cancer with wild-type EGFR
    Jo, Ukhyun
    Park, Kyong Hwa
    Whang, Young Mi
    Sung, Jae Sook
    Won, Nam Hee
    Park, Jong Kuk
    Kim, Yeul Hong
    ONCOTARGET, 2014, 5 (05) : 1265 - 1278
  • [43] Role of erlotinib in the treatment of advanced non-small-cell lung cancer patients with EGFR wild-type tumors
    Braun, Eduardo
    Bonomi, Philip
    LUNG CANCER MANAGEMENT, 2014, 3 (01) : 101 - 116
  • [44] Capmatinib plus nivolumab in pretreated patients with EGFR wild-type advanced non-small cell lung cancer
    Felip, Enriqueta
    Metro, Giulio
    Tan, Daniel S. W.
    Wolf, Juergen
    Mark, Michael
    Boyer, Michael
    Hughes, Brett G. M.
    Bearz, Alessandra
    Moro-Sibilot, Denis
    Le, Xiuning
    Puente, Javier
    Massuti, Bartomeu
    Tiedt, Ralph
    Wang, Yingying
    Xu, Chao
    Mardjuadi, Feby I.
    Cobo, Manuel
    LUNG CANCER, 2024, 192
  • [45] A phase II trial of erlotinib in patients with EGFR wild-type advanced non-small-cell lung cancer
    Kobayashi, Takashi
    Koizumi, Tomonobu
    Agatsuma, Toshihide
    Yasuo, Masanori
    Tsushima, Kenji
    Kubo, Keishi
    Eda, Seiichiro
    Kuraishi, Hiroshi
    Koyama, Shigeru
    Hachiya, Tsutomu
    Ohura, Nariaki
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2012, 69 (05) : 1241 - 1246
  • [46] A phase II trial of erlotinib in patients with EGFR wild-type advanced non-small-cell lung cancer
    Takashi Kobayashi
    Tomonobu Koizumi
    Toshihide Agatsuma
    Masanori Yasuo
    Kenji Tsushima
    Keishi Kubo
    Seiichiro Eda
    Hiroshi Kuraishi
    Shigeru Koyama
    Tsutomu Hachiya
    Nariaki Ohura
    Cancer Chemotherapy and Pharmacology, 2012, 69 : 1241 - 1246
  • [47] Transdermal fentanyl vs oral oxycodone plus naloxone prolonged release: Efficacy in pain control for stage IV cancer patients
    Prudente, A.
    Pepe, S.
    Scarpati, G. Della Vittoria
    Fusciello, C.
    Di Giulio, G.
    Faiola, V.
    Napoli, D.
    Cigolari, S.
    Serio, B.
    Guarrasi, R.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S275 - S275
  • [48] Combined oral prolonged-release oxycodone and naloxone in opioid-induced bowel dysfunction: review of efficacy and safety data in the treatment of patients experiencing chronic pain
    Clemens, Katri Elina
    Mikus, Gerd
    EXPERT OPINION ON PHARMACOTHERAPY, 2010, 11 (02) : 297 - 310
  • [49] Optimisation of EGFR TKI efficiency in the therapeutic scheme of EGFR wild-type lung cancer
    Cabart, Mathilde
    Raimbourg, Judith
    Lalier, Lisenn
    Bennouna, Jaafar
    Vallette, Francois
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [50] Association of systemic inflammation with survival in EGFR wild-type lung cancer
    Chen, X.
    Zhang, L.
    Liu, X.
    ANNALS OF ONCOLOGY, 2018, 29
12345